HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The effect of liraglutide on endothelial function in patients with type 2 diabetes.

Abstract
This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease. Patients were randomized to liraglutide, placebo or glimepiride. At baseline and Week 12, venous occlusion plethysmography was used to measure forearm blood flow (FBF) in response to acetylcholine (ACh) and sodium nitroprusside (SNP) before and after (L)-N(G)-monomethyl arginine (L-NMMA) infusion. At Week 12, ACh-mediated FBF increased with liraglutide and decreased with placebo; however, the between-treatment difference was not significant (p = 0.055). Inhibition of ACh-mediated FBF after L-NMMA infusion increased with liraglutide and decreased with placebo; this between-treatment difference was also not significant (p = 0.149). No change in FBF was observed with SNP. Liraglutide did not significantly impact endothelium-dependent vasodilation after 12 weeks; however, additional investigations looking at the effect of liraglutide on endothelial function in alternative vasculature and during the postprandial period are warranted.
AuthorsDebashis Nandy, Christopher Johnson, Rita Basu, Michael Joyner, Jason Brett, Claus Bo Svendsen, Ananda Basu
JournalDiabetes & vascular disease research (Diab Vasc Dis Res) Vol. 11 Issue 6 Pg. 419-30 (Nov 2014) ISSN: 1752-8984 [Electronic] England
PMID25212693 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© The Author(s) 2014.
Chemical References
  • Blood Glucose
  • C-Peptide
  • Hypoglycemic Agents
  • Insulin
  • Lipids
  • Nitroprusside
  • Liraglutide
  • Glucagon-Like Peptide 1
  • Glucagon
  • Acetylcholine
Topics
  • Acetylcholine
  • Aged
  • Blood Glucose (drug effects)
  • Blood Pressure (drug effects)
  • Body Weight (drug effects)
  • C-Peptide (blood)
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Endothelium, Vascular (drug effects)
  • Female
  • Glucagon (blood)
  • Glucagon-Like Peptide 1 (analogs & derivatives, pharmacology, therapeutic use)
  • Glucose Clamp Technique
  • Humans
  • Hypoglycemic Agents (pharmacology, therapeutic use)
  • Insulin (blood)
  • Lipids (blood)
  • Liraglutide
  • Male
  • Middle Aged
  • Nitroprusside
  • Plethysmography

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: